Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A
This month"s Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma"s L-CsA, inhaled liposomal cyclosporine A. In May, PARI Pharma received Orphan Drug Designation from the Food and Drug Administration for L-CsA, delivered via an Investigational eFlow Nebulizer System, for the prevention and treatment of bronchiolitis obliterans, a devastating, incurable disease of the small airways affecting approximately 60,000 patients worldwide.

QRESEARCH Team Welcome New Validation Of QRISK formula for identifying those most at risk of developing heart disease
The University of Nottingham and leading healthcare systems supplier EMIS welcomed a new, independent validation of the QRISK formula for identifying those most at risk of developing heart disease. The two organisations worked together, through the not-for-profit partnership QResearch, to develop the ground-breaking formula which has been strongly endorsed in new research published in the BMJ .
News of the day
John Muir Health Foundation Funds Advanced Robotic Technology For Minimally Invasive Surgery
John Muir Health Foundation, the charitable fundraising organization for all John Muir Health programs and services, has provided funding to enable John Muir Health to purchase two advanced high definition daVinci® Surgical Systems for its Walnut Creek and Concord campuses. Surgeons at John Muir Heath will use the daVinci® "robots" for a variety of minimally invasive urological, gynecological, gynecologic/oncologic and colorectal treatments.
Health Insurance

Editorial, Opinion Piece Discuss Issues Related To Routine HIV Testing

A recent directive to streamline the HIV testing consent process in Massachusetts as well as consent forms "no longer hav[ing] to accompany test specimens to the lab," are bringing "the state closer to a CDC recommendation that clinicians provide HIV screening on an opt-out basis," according to a Boston Globe editorial. "The opt-out provision is at the heart" of legislation sponsored by state Sen. Patricia Jehlen (D) that would end the state"s requirement of written consent for HIV testing "and instead have healthcare providers inform patients verbally that the test is planned but that they can decline it," the editorial states, adding, "The Jehlen bill would help destigmatize HIV testing itself" (7/6). Separately, an opinion piece in the Detroit Free Press - by David Share, medical director of the Corner Health Center and senior associate medical director of health care quality at Blue Cross Blue Shield of Michigan and Sandro Cinti, a clinical assistant professor in the Department of Internal Medicine at the University of Michigan-Ann Arbor - supports a Michigan bill (HB 4583) that would eliminate the written informed consent requirement in that state and replace it with a pamphlet and an informational opt-out form. Share and Cinti write of the current requirements, "These extraordinary precautions provide no protection, are not needed, and distract patients and health care professionals from other services and treatments that have the potential to improve patients" well-being," adding,"Routine HIV testing should be encouraged for early diagnosis and treatment of HIV infection" (Share/Cinti, 7/2). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009